May 2026 Research Update

This month, human evidence across many tested medicines still looked modest on average for overall ataxia scores, while laboratory and animal research focused on better ways to replace frataxin in the organs most affected by Friedreich ataxia. The contrast is that drug trials have clearer limits in what they have shown so far, while frataxin-delivery approaches are aiming for broader reach in the body but are not yet proven in people. Together, these studies sharpen the picture of where current evidence is firm (trial outcomes to date) and where it is still early (new delivery platforms). [1] [2] [3]

A Cochrane review pooling randomized trials of several medicines (including omaveloxolone, idebenone, and others) reported little to no difference versus placebo on overall ataxia rating scales after 12 months. Some outcomes were more uncertain, including heart structure measures and daily living activities, partly because fewer participants contributed data and results were less consistent. The same review found an uncertain safety signal because the available trials were not large enough to reliably detect uncommon serious problems. [1]

A separate meta-analysis looked only at omaveloxolone and combined controlled trials with longer-term and real-world follow-up without a matched control group. When all studies were pooled together, the average change from baseline in mFARS was close to no change, while subgroup results differed depending on study type and follow-up length. This mixed pattern highlights how strongly the conclusion can depend on whether there is a concurrent comparison group and on the time window being studied. [4]

Two preclinical studies tested frataxin replacement strategies designed to reach multiple tissues, including the heart and sensory nerve structures. One used an AAV gene therapy approach delivered into the fluid around the spinal cord, aiming to produce a frataxin variant that can be secreted and taken up by nearby cells; it reported broader frataxin signals across heart, dorsal root ganglia, and brain regions, along with improved movement outcomes in mouse models. The other used blood-forming stem cells engineered to secrete a cell-penetrating frataxin fusion protein, reporting rescue of cell defects in patient-derived cells and delayed motor symptom onset in an FRDA mouse model. [2] [3]

For patients, the most solid message this month is that across multiple randomized drug trials, the average change in overall ataxia scores at 12 months has been small, and some other outcomes remain uncertain because the evidence base is thin. The omaveloxolone-only meta-analysis adds context that results can look different in short controlled studies versus longer or real-world follow-up, but it cannot settle the question the way a directly controlled long-term study could. The frataxin delivery studies are early research in animals and cells, and they mainly matter as groundwork for future therapies rather than as evidence of benefit in people today. [1] [4] [2] [3]

This month added practical building blocks for tracking Friedreich ataxia by focusing on measures that reflect lived experience and nervous system function. A new patient-reported questionnaire captured communication problems, and simple electrical signal tests of hearing and vision were very often abnormal and lined up with clinical severity. In contrast, several blood markers measured in the same severity study did not show a consistent relationship with severity, suggesting they may be less useful for that specific purpose based on current data. [5] [6]

The COMATAX questionnaire was developed with patients and caregivers to describe communication-related disability, such as speaking clearly, being understood in conversation, and emotional impact of communication. In 93 people with Friedreich ataxia using a mobile app in French and German, COMATAX scores were consistent within the scale and lined up with existing speech and hearing questionnaires. It also separated groups by clinical severity and self-rated health, supporting that it measures something meaningful to daily life. [5]

In 29 adults with genetically confirmed Friedreich ataxia, brainstem auditory and visual evoked potentials (tests that measure timing of nerve signals after sounds or visual patterns) were frequently abnormal and were strongly related to mFARS severity scores. People with more abnormal results tended to have higher (worse) mFARS, and models that included these signal timings and disease duration explained a large share of the differences in mFARS. In the same study, measured blood markers (including neurofilament light and GFAP) did not show consistent links with mFARS. [6]

These studies mainly matter for how Friedreich ataxia can be followed in research studies and, over time, possibly in routine tracking of symptoms. COMATAX adds a structured way for patients to report communication challenges that might not be captured well by movement-focused scales, but it is not yet established for showing change over time. Evoked potential testing looked promising as a way to reflect current severity, while the tested blood markers did not track severity reliably in that small group, so it remains uncertain which blood tests are most informative for monitoring. [5] [6]

This month expanded what is being measured beyond movement symptoms, with new signals related to the heart, mental wellbeing, and underlying cell biology. A small human study suggested a 2-microRNA blood panel could help identify hypertrophic cardiomyopathy in Friedreich ataxia, and a multi-year cohort reported lower psychological resilience in people with Friedreich ataxia that tracked closely with depression and anxiety. Alongside these clinical observations, several lab studies proposed specific molecular changes that could be part of the disease process, but they remain early-stage. [7] [8] [9] [10] [11] [12]

For heart involvement, a case-control study measured a predefined set of circulating microRNAs in 34 people with Friedreich ataxia and 34 matched healthy controls. Two microRNAs (miR-323a-3p and miR-625-3p) together distinguished those with hypertrophic cardiomyopathy with an AUC around 0.81 in the reported model, and the authors noted this panel could outperform traditional protein biomarkers in their dataset. Because the cohort was small and limited to Caucasian participants, this needs confirmation in broader groups before it can be considered reliable. [7]

For mental wellbeing, a longitudinal study following adults for up to 6 years found that people with Friedreich ataxia had lower resilience scores than healthy controls at baseline. Resilience scores moved in the opposite direction of depression and anxiety scores, meaning lower resilience went together with higher symptoms on those questionnaires. The study also observed a drop during the COVID-19 period in the patient group that did not fully return to earlier levels by the end of follow-up, although some analyses did not reach statistical significance. [8]

Several lab studies focused on mechanisms that might contribute to nervous system damage or low frataxin. In human dorsal root ganglia tissue from Friedreich ataxia, one group reported higher KIT receptor signaling and a newly observed truncated KIT protein in satellite cells, pointing to a possible pathway involved in sensory nerve pathology. Another study linked FXN gene positioning at the edge of the nucleus to an imbalance between transcription and cohesin activity, and reported that restoring either transcription or cohesin activity repositioned FXN and reactivated its expression in their experimental system. [9] [10]

Two additional early studies provided research tools and molecular details rather than patient-ready tests. Patient-derived cerebellar organoids showed Friedreich ataxia-related changes that were reported as reversible with HDAC inhibitors or CRISPR gene editing, offering a platform for studying cerebellar cell types in the lab. A computational study of frataxin suggested an iron binding pocket near the C-terminus may be energetically favored over the classic acidic ridge site, supporting a model where more than one binding site could matter for frataxin function. [11] [12]

For patients, the heart microRNA panel and the resilience findings may feel most immediately relatable, but both are still mainly about understanding and measurement rather than changing care right now. The microRNA results are an early signal that a blood test could one day help identify or track FA-related thickened-heart disease, but it remains uncertain how well it would work in other clinics, ethnic groups, or over time. The resilience study clarifies that emotional strain and resilience are tightly linked with depression and anxiety symptoms in Friedreich ataxia, and it provides a clearer picture of how these scores can shift with major life disruptions. The lab studies help explain possible disease pathways and provide experimental models, but they are not yet tests or treatments used in everyday practice. [7] [8] [9] [10] [11] [12]